Evaluation of cerebrospinal fluid glycoprotein NMB (GPNMB) as a potential biomarker for Alzheimer's disease.
Alzheimer’s disease
Biomarker
Cerebrospinal fluid
GPNMB
Immunoassay
Inflammation
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
04 05 2021
04 05 2021
Historique:
received:
03
02
2021
accepted:
12
04
2021
entrez:
5
5
2021
pubmed:
6
5
2021
medline:
25
6
2021
Statut:
epublish
Résumé
Alzheimer's disease (AD) is a neurodegenerative disorder associated with extracellular amyloid-β peptide deposition and progressive neuron loss. Strong evidence supports that neuroinflammatory changes such as the activation of astrocytes and microglia cells are important in the disease process. Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a transmembrane glycoprotein that has recently been associated with an emerging role in neuroinflammation, which has been reported to be increased in post-mortem brain samples from AD and Parkinson's disease patients. The present study describes the partial "fit for purpose" validation of a commercially available immunoassay for the determination of GPNMB levels in the cerebrospinal fluid (CSF). We further assessed the applicability of GPNMB as a potential biomarker for AD in two different cohorts that were defined by biomarker-supported clinical diagnosis or by neuroimaging with amyloid positron emission tomography, respectively. The results indicated that CSF GPNMB levels could not distinguish between AD or controls with other neurological diseases but correlated with other parameters such as aging and CSF pTau levels. The findings of this study do not support GPNMB in CSF as a valuable neurochemical diagnostic biomarker of AD but warrant further studies employing healthy control individuals.
Sections du résumé
BACKGROUND
Alzheimer's disease (AD) is a neurodegenerative disorder associated with extracellular amyloid-β peptide deposition and progressive neuron loss. Strong evidence supports that neuroinflammatory changes such as the activation of astrocytes and microglia cells are important in the disease process. Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a transmembrane glycoprotein that has recently been associated with an emerging role in neuroinflammation, which has been reported to be increased in post-mortem brain samples from AD and Parkinson's disease patients.
METHODS
The present study describes the partial "fit for purpose" validation of a commercially available immunoassay for the determination of GPNMB levels in the cerebrospinal fluid (CSF). We further assessed the applicability of GPNMB as a potential biomarker for AD in two different cohorts that were defined by biomarker-supported clinical diagnosis or by neuroimaging with amyloid positron emission tomography, respectively.
RESULTS
The results indicated that CSF GPNMB levels could not distinguish between AD or controls with other neurological diseases but correlated with other parameters such as aging and CSF pTau levels.
CONCLUSIONS
The findings of this study do not support GPNMB in CSF as a valuable neurochemical diagnostic biomarker of AD but warrant further studies employing healthy control individuals.
Identifiants
pubmed: 33947460
doi: 10.1186/s13195-021-00828-1
pii: 10.1186/s13195-021-00828-1
pmc: PMC8097817
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
GPNMB protein, human
0
Glycoproteins
0
Membrane Glycoproteins
0
Peptide Fragments
0
tau Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
94Références
Alzheimer's Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2020;2020(16):391–460.
Querfurth HW, LaFerla FM. Alzheimer’s disease. New Engl J Med. 2010;362(4):329–44. https://doi.org/10.1056/NEJMra0909142 .
doi: 10.1056/NEJMra0909142
pubmed: 20107219
Nhan HS, Chiang K, Koo EH. The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes. Acta Neuropathol. 2015;129(1):1–19. https://doi.org/10.1007/s00401-014-1347-2 .
doi: 10.1007/s00401-014-1347-2
pubmed: 25287911
Nisbet RM, Polanco JC, Ittner LM, Gotz J. Tau aggregation and its interplay with amyloid-beta. Acta Neuropathol. 2015;129(2):207–20. https://doi.org/10.1007/s00401-014-1371-2 .
doi: 10.1007/s00401-014-1371-2
pubmed: 25492702
Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, Fagan AM, Hampel H, Mielke MM, Mikulskis A, O’Bryant S, Scheltens P, Sevigny J, Shaw LM, Soares HD, Tong G, Trojanowski JQ, Zetterberg H, Blennow K. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol. 2018;136(6):821–53. https://doi.org/10.1007/s00401-018-1932-x .
doi: 10.1007/s00401-018-1932-x
pubmed: 30488277
pmcid: 6280827
Olsson B, Lautner R, Andreasson U, Öhrfelt A, Portelius E, Bjerke M, Hölttä M, Rosén C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H. CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673–84. https://doi.org/10.1016/S1474-4422(16)00070-3 .
doi: 10.1016/S1474-4422(16)00070-3
pubmed: 27068280
Kuhlmann J, Andreasson U, Pannee J, Bjerke M, Portelius E, Leinenbach A, Bittner T, Korecka M, Jenkins RG, Vanderstichele H, Stoops E, Lewczuk P, Shaw LM, Zegers I, Schimmel H, Zetterberg H, Blennow K. CSF Aβ1–42 – an excellent but complicated Alzheimer’s biomarker – a route to standardisation. Clin Chim Acta. 2017;467:27–33. https://doi.org/10.1016/j.cca.2016.05.014 .
doi: 10.1016/j.cca.2016.05.014
pubmed: 27216941
Lewczuk P, Riederer P, O’Bryant SE, Verbeek MM, Dubois B, Visser PJ, Jellinger KA, Engelborghs S, Ramirez A, Parnetti L, Jack CR Jr, Teunissen CE, Hampel H, Lleó A, Jessen F, Glodzik L, de Leon MJ, Fagan AM, Molinuevo JL, Jansen WJ, Winblad B, Shaw LM, Andreasson U, Otto M, Mollenhauer B, Wiltfang J, Turner MR, Zerr I, Handels R, Thompson AG, Johansson G, Ermann N, Trojanowski JQ, Karaca I, Wagner H, Oeckl P, van Waalwijk van Doorn L, Bjerke M, Kapogiannis D, Kuiperij HB, Farotti L, Li Y, Gordon BA, Epelbaum S, Vos SJB, Klijn CJM, van Nostrand WE, Minguillon C, Schmitz M, Gallo C, Lopez Mato A, Thibaut F, Lista S, Alcolea D, Zetterberg H, Blennow K, Kornhuber J, on Behalf of the Members of the WFSBP Task Force Working on this Topic: Peter Riederer, Carla Gallo, Dimitrios Kapogiannis, Andrea Lopez Mato, Florence Thibaut. Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: an update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World J Biol Psychiatry. 2018;19(4):244–328. https://doi.org/10.1080/15622975.2017.1375556 .
doi: 10.1080/15622975.2017.1375556
pubmed: 29076399
Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. JAMA Neurol. 2014;71(10):1282–9. https://doi.org/10.1001/jamaneurol.2014.1358 .
doi: 10.1001/jamaneurol.2014.1358
pubmed: 25155658
Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, Hansson O. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 2017;74(12):1492–501. https://doi.org/10.1001/jamaneurol.2017.2814 .
doi: 10.1001/jamaneurol.2017.2814
pubmed: 29114726
pmcid: 5822196
Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R, Buck K, Zink K, Rabe C, Blennow K, Shaw LM, for the Swedish BioFINDER study group, Alzheimer's Disease Neuroimaging Initiative. CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470–81. https://doi.org/10.1016/j.jalz.2018.01.010 .
doi: 10.1016/j.jalz.2018.01.010
pubmed: 29499171
pmcid: 6119541
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918–34. https://doi.org/10.1016/j.cell.2010.02.016 .
doi: 10.1016/j.cell.2010.02.016
pubmed: 20303880
pmcid: 2873093
Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, Koistinaho J, Latz E, Halle A, Petzold GC, Town T, Morgan D, Shinohara ML, Perry VH, Holmes C, Bazan NG, Brooks DJ, Hunot S, Joseph B, Deigendesch N, Garaschuk O, Boddeke E, Dinarello CA, Breitner JC, Cole GM, Golenbock DT, Kummer MP. Neuroinflammation in Alzheimer’s disease. Lancet Neurol. 2015;14(4):388–405. https://doi.org/10.1016/S1474-4422(15)70016-5 .
doi: 10.1016/S1474-4422(15)70016-5
pubmed: 25792098
pmcid: 5909703
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368(2):107–16. https://doi.org/10.1056/NEJMoa1211103 .
doi: 10.1056/NEJMoa1211103
pubmed: 23150908
Karch CM, Goate AM. Alzheimer’s disease risk genes and mechanisms of disease pathogenesis. Biol Psychiatry. 2015;77(1):43–51. https://doi.org/10.1016/j.biopsych.2014.05.006 .
doi: 10.1016/j.biopsych.2014.05.006
pubmed: 24951455
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J, Alzheimer Genetic Analysis Group. TREM2 variants in Alzheimer’s disease. N Engl J Med. 2013;368(2):117–27. https://doi.org/10.1056/NEJMoa1211851 .
doi: 10.1056/NEJMoa1211851
pubmed: 23150934
Paloneva BMJ, Autti T, Raininko R, Partanen J, Salonen O, Puranen M, Hakola P, Haltia M. CNS manifestations of Nasu–Hakola disease: a frontal dementia with bone cysts. Neurology. 2001;56(11):1552–8. https://doi.org/10.1212/WNL.56.11.1552 .
doi: 10.1212/WNL.56.11.1552
pubmed: 11402114
Bianchin MM, Lima JE, Natel J, Sakamoto AC. The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology. 2006;66(4):615–6. https://doi.org/10.1212/01.wnl.0000216105.11788.0f .
doi: 10.1212/01.wnl.0000216105.11788.0f
pubmed: 16505336
Weissmann R, Huttenrauch M, Kacprowski T, Bouter Y, Pradier L, Bayer TA, Kuss AW, Wirths O. Gene expression profiling in the APP/PS1KI mouse model of familial Alzheimer’s disease. J Alzheimers Dis. 2016;50(2):397–409. https://doi.org/10.3233/JAD-150745 .
doi: 10.3233/JAD-150745
pubmed: 26639971
Hüttenrauch M, Ogorek I, Klafki H, Otto M, Stadelmann C, Weggen S, Wiltfang J, Wirths O. Glycoprotein NMB: a novel Alzheimer’s disease associated marker expressed in a subset of activated microglia. Acta Neuropathol Commun. 2018;6(1):108. https://doi.org/10.1186/s40478-018-0612-3 .
doi: 10.1186/s40478-018-0612-3
pubmed: 30340518
pmcid: 6194687
Weterman MAJ, Ajubi N, van Dinter IMR, Degen WGJ, van Muijen GNP, Ruiter DJ, HPJ B. nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts. Int J Cancer. 1995;60(1):73–81. https://doi.org/10.1002/ijc.2910600111 .
doi: 10.1002/ijc.2910600111
pubmed: 7814155
Ripoll VM, Irvine KM, Ravasi T, Sweet MJ, Hume DA. Gpnmb is induced in macrophages by IFN-γ and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses. J Immunol. 2007;178(10):6557–66. https://doi.org/10.4049/jimmunol.178.10.6557 .
doi: 10.4049/jimmunol.178.10.6557
pubmed: 17475886
Huang J-J, Ma W-J, Yokoyama S. Expression and immunolocalization of Gpnmb, a glioma-associated glycoprotein, in normal and inflamed central nervous systems of adult rats. Brain Behav. 2012;2(2):85–96. https://doi.org/10.1002/brb3.39 .
doi: 10.1002/brb3.39
pubmed: 22574278
pmcid: 3345354
J-i S, Kino Y, Yanaizu M, Ishida T, Saito Y. Microglia express GPNMB in the brains of Alzheimer’s disease and Nasu-Hakola disease. Intractable Rare Dis Res. 2019;8:120–8.
doi: 10.5582/irdr.2019.01049
Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD, Sánchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschütz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, van Broeckhoven C, Zetterberg H, Nellgård B, Blennow K, Crispin A, Ewers M, Haass C. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer’s disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8(5):466–76. https://doi.org/10.15252/emmm.201506123 .
doi: 10.15252/emmm.201506123
pubmed: 26941262
pmcid: 5120370
Kleinberger G, Yamanishi Y, Suárez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, Wenninger-Weinzierl A, Mazaheri F, et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med. 2014;6:243ra286.
doi: 10.1126/scitranslmed.3009093
Rose AAN, Annis MG, Dong Z, Pepin F, Hallett M, Park M, Siegel PM. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with Angiogenic properties. Plos One. 2010;5(8):e12093. https://doi.org/10.1371/journal.pone.0012093 .
doi: 10.1371/journal.pone.0012093
pubmed: 20711474
pmcid: 2919417
Shalem O, Sanjana NE, Hartenian E, Shi X, Scott DA, Mikkelsen TS, Heckl D, Ebert BL, Root DE, Doench JG, Zhang F. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2014;343(6166):84–7. https://doi.org/10.1126/science.1247005 .
doi: 10.1126/science.1247005
pubmed: 24336571
pmcid: 24336571
Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11(8):783–4. https://doi.org/10.1038/nmeth.3047 .
doi: 10.1038/nmeth.3047
pubmed: 25075903
pmcid: 4486245
Walter S, Jumpertz T, Hüttenrauch M, Ogorek I, Gerber H, Storck SE, Zampar S, Dimitrov M, Lehmann S, Lepka K, Berndt C, Wiltfang J, Becker-Pauly C, Beher D, Pietrzik CU, Fraering PC, Wirths O, Weggen S. The metalloprotease ADAMTS4 generates N-truncated Aβ4–x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimer’s disease. Acta Neuropathol. 2019;137(2):239–57. https://doi.org/10.1007/s00401-018-1929-5 .
doi: 10.1007/s00401-018-1929-5
pubmed: 30426203
Klafki HW, Hafermann H, Bauer C, Haussmann U, Kraus I, Schuchhardt J, Muck S, Scherbaum N, Wiltfang J. Validation of a commercial chemiluminescence immunoassay for the simultaneous measurement of three different amyloid-beta peptides in human cerebrospinal fluid and application to a clinical cohort. J Alzheimers Dis. 2016;54(2):691–705. https://doi.org/10.3233/JAD-160398 .
doi: 10.3233/JAD-160398
pubmed: 27567847
Bouter C, Vogelgsang J, Wiltfang J. Comparison between amyloid-PET and CSF amyloid-β biomarkers in a clinical cohort with memory deficits. Clin Chim Acta. 2019;492:62–8. https://doi.org/10.1016/j.cca.2019.02.005 .
doi: 10.1016/j.cca.2019.02.005
pubmed: 30735665
Calero O, Hortigüela R, Bullido MJ, Calero M. Apolipoprotein E genotyping method by real time PCR, a fast and cost-effective alternative to the TaqMan® and FRET assays. J Neurosci Methods. 2009;183(2):238–40. https://doi.org/10.1016/j.jneumeth.2009.06.033 .
doi: 10.1016/j.jneumeth.2009.06.033
pubmed: 19583979
Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–5. https://doi.org/10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3 .
doi: 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
Perkins NJ, Schisterman EF. The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006;163(7):670–5. https://doi.org/10.1093/aje/kwj063 .
doi: 10.1093/aje/kwj063
pubmed: 16410346
Sala Frigerio C, Wolfs L, Fattorelli N, Thrupp N, Voytyuk I, Schmidt I, Mancuso R, Chen W-T, Woodbury ME, Srivastava G, et al. The major risk factors for Alzheimers disease: age, sex, and genes modulate the microglia response to Abeta plaques. Cell Rep. 2019;27:1293–1306.e1296.
doi: 10.1016/j.celrep.2019.03.099
Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A, Walker AJ, Gergits F, Segel M, Nemesh J, Marsh SE, Saunders A, Macosko E, Ginhoux F, Chen J, Franklin RJM, Piao X, McCarroll SA, Stevens B. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. Immunity. 2019;50(1):253–71 e256. https://doi.org/10.1016/j.immuni.2018.11.004 .
doi: 10.1016/j.immuni.2018.11.004
pubmed: 30471926
Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, Baruch K, Lara-Astaiso D, Toth B, et al. A unique microglia type associated with restricting fevelopment of Alzheimer’s disease. Cell. 2017;169:1276–1290.e1217.
doi: 10.1016/j.cell.2017.05.018
Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O’Loughlin E, Xu Y, Fanek Z, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47:566–581.e569.
doi: 10.1016/j.immuni.2017.08.008
Zhu S, Wuolikainen A, Wu J, Öhman A, Wingsle G, Moritz T, Andersen PM, Forsgren L, Trupp M. Targeted multiple reaction monitoring analysis of CSF identifies UCHL1 and GPNMB as candidate biomarkers for ALS. J Mol Neurosci. 2019;69(4):643–57. https://doi.org/10.1007/s12031-019-01411-y .
doi: 10.1007/s12031-019-01411-y
pubmed: 31721001
pmcid: 6858390
Oeckl P, Weydt P, Thal DR, Weishaupt JH, Ludolph AC, Otto M. Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP 2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathol. 2020;139(1):119–34. https://doi.org/10.1007/s00401-019-02093-x .
doi: 10.1007/s00401-019-02093-x
pubmed: 31701227
Furochi H, Tamura S, Mameoka M, Yamada C, Ogawa T, Hirasaka K, Okumura Y, Imagawa T, Oguri S, Ishidoh K, Kishi K, Higashiyama S, Nikawa T. Osteoactivin fragments produced by ectodomain shedding induce MMP-3 expression via ERK pathway in mouse NIH-3T3 fibroblasts. FEBS Lett. 2007;581(30):5743–50. https://doi.org/10.1016/j.febslet.2007.11.036 .
doi: 10.1016/j.febslet.2007.11.036
pubmed: 18036345
Hoashi T, Sato S, Yamaguchi Y, Passeron T, Tamaki K, Hearing VJ. Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein. FASEB J. 2010;24(5):1616–29. https://doi.org/10.1096/fj.09-151019 .
doi: 10.1096/fj.09-151019
pubmed: 20056711
pmcid: 2879953
Utsunomiya K, Owaki K, Okumura Y, Yano M, Oto T, Suzuki E, Tamura S, Abe T, Kohno S, Ohno A, et al. An intracellular fragment of osteoactivin formed by ectodomain shedding translocated to the nucleoplasm and bound to RNA binding proteins. Biosci Biotechnol Biochem. 2012;76(12):2225–9. https://doi.org/10.1271/bbb.120515 .
doi: 10.1271/bbb.120515
pubmed: 23221696
Zigdon H, Savidor A, Levin Y, Meshcheriakova A, Schiffmann R, Futerman AH. Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease. Plos One. 2015;10(3):e0120194. https://doi.org/10.1371/journal.pone.0120194 .
doi: 10.1371/journal.pone.0120194
pubmed: 25775479
pmcid: 4361053
Kramer G, Wegdam W, Donker-Koopman W, Ottenhoff R, Gaspar P, Verhoek M, Nelson J, Gabriel T, Kallemeijn W, Boot RG, Laman JD, Vissers JPC, Cox T, Pavlova E, Moran MT, Aerts JM, Eijk M. Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models. FEBS Open Bio. 2016;6(9):902–13. https://doi.org/10.1002/2211-5463.12078 .
doi: 10.1002/2211-5463.12078
pubmed: 27642553
pmcid: 5011488
Moloney EB, Moskites A, Ferrari EJ, Isacson O, Hallett PJ. The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson’s disease patients and increases after lysosomal stress. Neurobiol Dis. 2018;120:1–11. https://doi.org/10.1016/j.nbd.2018.08.013 .
doi: 10.1016/j.nbd.2018.08.013
pubmed: 30149180
pmcid: 6748034
Budge KM, Neal ML, Richardson JR, Safadi FF. Transgenic overexpression of GPNMB protects against MPTP-induced neurodegeneration. Mol Neurobiol. 2020;57(7):2920–33. https://doi.org/10.1007/s12035-020-01921-6 .
doi: 10.1007/s12035-020-01921-6
pubmed: 32436108
Wang H, Dey KK, Chen P-C, Li Y, Niu M, Cho J-H, Wang X, Bai B, Jiao Y, Chepyala SR, Haroutunian V, Zhang B, Beach TG, Peng J. Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease. Mol Neurodegener. 2020;15(1):43. https://doi.org/10.1186/s13024-020-00384-6 .
doi: 10.1186/s13024-020-00384-6
pubmed: 32711556
pmcid: 7382148
Bai B, Wang X, Li Y, Chen P-C, Yu K, Dey KK, Yarbro JM, Han X, Lutz BM, Rao S, Jiao Y, Sifford JM, Han J, Wang M, Tan H, Shaw TI, Cho JH, Zhou S, Wang H, Niu M, Mancieri A, Messler KA, Sun X, Wu Z, Pagala V, High AA, Bi W, Zhang H, Chi H, Haroutunian V, Zhang B, Beach TG, Yu G, Peng J. Deep multilayer brain proteomics identifies molecular networks in Alzheimer’s disease progression. Neuron. 2020;105(6):975–91. https://doi.org/10.1016/j.neuron.2019.12.015 .
doi: 10.1016/j.neuron.2019.12.015
pubmed: 31926610
pmcid: 7318843
Kim Y, Rosenberg P, Oh E. A review of diagnostic impact of amyloid positron emission tomography imaging in clinical practice. Dement Geriatr Cogn Disord. 2018;46(3-4):154–67. https://doi.org/10.1159/000492151 .
doi: 10.1159/000492151
pubmed: 30199882
Sabri O, Sabbagh MN, Seibyl J, Barthel H, Akatsu H, Ouchi Y, Senda K, Murayama S, Ishii K, Takao M, Beach TG, Rowe CC, Leverenz JB, Ghetti B, Ironside JW, Catafau AM, Stephens AW, Mueller A, Koglin N, Hoffmann A, Roth K, Reininger C, Schulz-Schaeffer WJ, Florbetaben Phase 3 Study Group. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: phase 3 study. Alzheimers Dement. 2015;11(8):964–74. https://doi.org/10.1016/j.jalz.2015.02.004 .
doi: 10.1016/j.jalz.2015.02.004
pubmed: 25824567
Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(3). https://doi.org/10.1101/cshperspect.a006312 .
Stratoulias V, Venero JL, Tremblay M-È, Joseph B. Microglial subtypes: diversity within the microglial community. EMBO J. 2019;38:e101997.
doi: 10.15252/embj.2019101997